Medicine, Hematology Oncology Division

Grants

Grants per year 1995 2007 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2028

• 468 Active
• 1104 Finished

Grants per year

Search results

• Agmt 04/16/10: DRUG COMPLETE: Prospective, Longitudinal, Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma

  Winter, J. N.

  Advanced Clinical Trial Solutions, LLC, Allos Therapeutics

  4/16/10 → 4/30/21

  Project: Research project

• Epigenomic Priming as an Immunotherapy Enhancer in Ovarian Cancer

  Matei, D. E., Kocherginsky, M., Shahabi, S., Wei, J. & Zhang, B.

  U.S. Army Medical Research and Materiel Command

  5/1/17 → 4/30/21

  Project: Research project

  • guadecitabine 100%
  • pembrolizumab 41%
  • Ovarian Neoplasms 28%
  • Immunotherapy 27%
  • Epigenomics 27%

• Prot #AG221-C-001: A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation

  Altman, J. K.

  INC Research, LLC, Agios Pharmaceuticals, Inc.

  4/8/14 → 4/30/21

  Project: Research project

• Prot #M14-358: A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are ≥ 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy

  Frankfurt, O.

  INC Research, LLC, AbbVie Inc.

  4/23/15 → 4/23/21

  Project: Research project

• Prot #CO40016: A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With Pik3ca/Akt1/Pten-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone

  Gradishar, W. J.

  Syneos Health, Inc., Genentech, Inc.

  4/19/18 → 4/19/21

  Project: Research project

• Prot #LYC-55716-1001: A Phase 1/2A, Multicenter, Open-Label Study of LYC-55716 in Adult Subjects with Locally Advanced or Metastatic Cancer

  Mahalingam, D.

  PRA Health Sciences, Lycera Corp.

  4/19/18 → 4/19/21

  Project: Research project

• Prot #MK3475-055: A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab

  Agulnik, M.

  Merck Sharp & Dohme Corporation

  4/17/15 → 4/17/21

  Project: Research project

• VA IPA in support of Jianghong Wang

  Eklund, E. A.

  Jesse Brown VA Medical Center

  7/1/19 → 4/2/21

  Project: Research project

  • Leukemia 100%
  • Myeloid Leukemia 99%
  • Myeloid Cells 83%
  • Proteins 44%
  • Immunoprecipitation 39%

• Triad1 regulates myelopoiesis and functions as a leukemia suppressor

  Eklund, E. A. & Wang, H.

  National Cancer Institute

  4/1/15 → 3/31/21

  Project: Research project

  • Acute Myeloid Leukemia 100%
  • Myelopoiesis 88%
  • Leukemia 66%
  • antineoplaston A10 46%
  • Integrins 31%

• Novel Agents for the Treatment of Malignancies

  Platanias, L. C.

  MPN Research Foundation

  12/1/17 → 3/31/21

  Project: Research project

  • Interferons 100%
  • Interferon-alpha 85%
  • Interferon Type I 64%
  • Growth Factor Receptors 64%
  • Neoplasms 60%

• Prot #201973: A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer

  Gradishar, W. J.

  Parexel, GlaxoSmithKline LLC

  3/14/18 → 3/14/21

  Project: Research project

• Prot #CPDR001XUS01: Modular Phase 2 Study to Link Combination Immune-Therapy to Patients with Advanced Solid and Hematologic Malignancies Module 9: PDR001 Plus LAG525 for Patients with Advanced Solid and Hematologic Malignancies

  Mahalingam, D.

  United BioSource LLC, Novartis Pharmaceuticals Corporation

  2/23/18 → 2/28/21

  Project: Research project

• Prot #C34002: An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

  Frankfurt, O. & Kaplan, J. B.

  Quintiles, Inc., Millennium Pharmaceuticals, Inc

  2/25/15 → 2/28/21

  Project: Research project

• ECOG-ACRIN Operations Center: Nursing Committee

  Benson III, A. B.

  ECOG-ACRIN Medical Research Foundation, Inc., National Cancer Institute

  3/29/19 → 2/28/21

  Project: Research project

  • project 100%

• Prot# E7080-G000-303: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in (131) I-Refractory Differentiated Thyroid Cancer

  Agulnik, M.

  PPD Development, Eisai, Inc.

  2/27/12 → 2/27/21

  Project: Research project

• Prot #CLTR0310-301: PHASE III, MULTICENTER, RANDOMIZED, TRIAL OF CPX-351 (CYTARABINE: DAUNORUBICIN) LIPOSOME INJECTION VERSUS CYTARABINE AND DAUNORUBICIN IN PATIENTS 60-75 YEARS OF AGE WITH UNTREATED HIGH RISK (SECONDARY) AML

  Frankfurt, O.

  Celator Pharmaceuticals, Inc.

  2/19/13 → 2/19/21

  Project: Research project

• Prot #H3B-6527-G000-101: An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

  Kalyan, A.

  PPD Investigator Services, LLC, H3 Biomedicine Inc.

  2/14/18 → 2/14/21

  Project: Research project

• Understanding Mechanisms of Immune Checkpoint Inhibitor Induced Colitis in Melanoma

  Sosman, J. A.

  Melanoma Research Foundation

  2/1/19 → 2/1/21

  Project: Research project

  • Colitis 100%
  • Melanoma 71%
  • Allergy and Immunology 46%
  • Immunotherapy 38%
  • T-Lymphocytes 26%

• Prot #AG120-C-005: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

  Kalyan, A.

  DrugDev Inc., Agios Pharmaceuticals, Inc.

  1/25/18 → 1/25/21

  Project: Research project

• Prot #INCB50465-204: A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)

  Ma, S.

  Covance Inc., Incyte Corporation

  1/24/18 → 1/24/21

  Project: Research project

• Image-guided Interventional Combination Liver Cancer Immunotherapy

  Yaghmai, V., Zhang, Z., Benson III, A. B., Ji, P., Salem, R. & Velichko, Y.

  National Cancer Institute

  3/15/20 → 1/2/21

  Project: Research project

  • Sorafenib 100%
  • Adoptive Immunotherapy 80%
  • Natural Killer Cells 75%
  • Adoptive Transfer 70%
  • Immunotherapy 62%

• A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal

  Hussain, M.

  AstraZeneca Pharmaceuticals LP

  9/26/17 → 1/1/21

  Project: Research project

• A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study).

  Patel, J. D.

  Hope Foundation

  1/1/20 → 12/31/20

  Project: Research project

  • Non-Small Cell Lung Carcinoma 100%
  • Immunotherapy 98%
  • Lung Neoplasms 88%
  • Biomarkers 72%
  • Costs and Cost Analysis 46%

• Utilization of Clinomic Outcomes, Patient-Derived Xenografts (Avatars), and Next Generation Sequencing Data

  Benson III, A. B.

  Nathan Cummings Foundation

  5/1/17 → 12/31/20

  Project: Research project

  • Heterografts 100%
  • High-Throughput Nucleotide Sequencing 85%
  • Medicine 40%
  • Research Personnel 38%
  • Therapeutics 18%

• Prot #SCRX003-001: A Phase 1a/1b Dose Escalation and Expansion Study of Single-Agent SC-003 in Subjects with Platinum-Resistant/Refractory Ovarian Cancer

  Matei, D. E.

  Novella Clinical, LLC, AbbVie Stemcentrx LLC

  9/11/17 → 12/31/20

  Project: Research project